Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Room

JDRF Canada responds to INESS recommendations regarding Dexcom G6 Continuous Glucose Monitor

Toronto, Ontario – February 27, 2020 – JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, is hopeful that the Government of Quebec might still consider provincial coverage for Continuous Glucose Monitoring (CGM) in spite of a report released this month by the Institut national d’excellence en santé et services sociaux (INESS).

Interview opportunity: JDRF celebrates the announcement of Dexcom G6 CGM System’s Availability in Canada

JDRF shares the excitement of the type 1 diabetes community around today’s arrival of the Dexcom G6,” said Dave Prowten, President and CEO of JDRF Canada. “While JDRF remains focused on our goal to cure type 1 diabetes, we welcome the arrival of new and innovative technologies like this that help Canadians living with the disease live easier, healthier, safer lives.”

Statement by Dave Prowten, President and CEO JDRF Canada

JDRF has been closely monitoring developments rising from the recent announcement of a “Safe Importation Action Plan” by the United States Department of Health & Human Services (HHS) and the Food and Drug Administration (FDA) to facilitate the importation of drugs that were intended for other markets, specifically Canada.

B.C. youth Samir Dattani to represent Canadians with type 1 diabetes in Washington, D.C.

British Columbia, July 4, 2019 – 16-year-old Samir Dattani, a long-time type 1 diabetes advocate from Vancouver’s Westside-Kerrisdale neighbourhood, is set to join hundreds of delegates from the United States and around the world at Juvenile Diabetes Research Foundation’s 2019 Children’s Congress in Washington, D.C. from July 8 – 10, where he will represent Canadians living with type 1 diabetes (T1D).

JDRF welcomes Disability Advisory Committee’s recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach

JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) First Annual Report, in particular, the DAC’s recommendation that all Canadians receiving life-sustaining therapy should qualify for the Disability Tax Credit (DTC).

Donate | Donnez